Dong Sung Pharm's Largest Shareholder Brand Refactoring: "The Key to Rehabilitation Is Establishing a Responsible Structure, Not Just Funding"
As market attention focuses on the acquisition entity and the size of investment regarding the rehabilitation proceedings of Dong Sung Pharm, a representative from Brand Refactoring stated on March 12, 2026, that establishing a responsible structure for management risks and disclosure issues should take priority over injecting funds during the rehabilitation process.
A Brand Refactoring official said, "While discussions on rehabilitation often center around the scale of investment or who the acquirer will be, in this case, the crucial factor is how the company will address the management risks and disclosure issues that have led to its current situation."
According to a disclosure, Dong Sung Pharm triggered a substantive review of continued listing eligibility on June 25, 2025, after announcing 'occurrence of embezzlement and breach of trust allegations.' Subsequently, the Korea Exchange decided to place Dong Sung Pharm under review by the Corporate Review Committee on July 16, 2025.
The Korea Exchange then granted Dong Sung Pharm a grace period for improvement until May 13, 2026, while deciding to maintain the suspension of trading during this period, as announced on August 13, 2025. At the time, the Korea Exchange stated that, in determining whether to maintain listing eligibility, it would consider not only the company's business continuity but also management transparency, public interest, and investor protection.
Sanctions related to disclosure continued as well. In July 2025, the Korea Exchange designated Dong Sung Pharm as an unfaithful disclosure entity and determined that the disclosure made on June 23, 2025, regarding 'explanation of rumors or media reports' was false or erroneous. As a result, Dong Sung Pharm was penalized with 8.5 penalty points and a disclosure violation fine of 85 million won.
Additional disclosure issues arose afterwards. In October 2025, Dong Sung Pharm received preliminary notice of being designated as an unfaithful disclosure entity for delayed disclosure of lawsuits and court rulings related to a management control dispute, and the designation was later finalized.
Brand Refactoring maintains that addressing these management and disclosure issues is a critical aspect of the rehabilitation process.
A company official commented, "In the course of rehabilitation, it will be more important to resolve and improve the management and disclosure risks that have brought the company to its current state than to simply inject new funds."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, Dong Sung Pharm's rehabilitation plan is expected to be reviewed by creditors and stakeholders at a future meeting of interested parties.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.